@Article{096504021X16240202940003,
AUTHOR = {Chang Li, Xiaoping Li, Shuohui Gao, Chang Li, Lianjun Ma},
TITLE = {MicroRNA-133a Inhibits Proliferation of Gastric Cancer Cells  by Downregulating ERBB2 Expression},
JOURNAL = {Oncology Research},
VOLUME = {28},
YEAR = {2020},
NUMBER = {7-8},
PAGES = {819--822},
URL = {http://www.techscience.com/or/v28n7-8/48472},
ISSN = {1555-3906},
ABSTRACT = {Gastric cancer is the fourth most common type of cancer and the second highest leading cause of cancer-related 
deaths worldwide. It has already been established that miR-133a is involved in gastric cancer. In this study, we 
investigated the molecular mechanisms by which miR-133a inhibits the proliferation of gastric cancer cells. 
We analyzed the proliferative capacity of human gastric cancer cells SNU-1 using an MTT assay. Cell apoptosis was determined using flow cytometry. The expression levels of ERBB2, p-ERK1/2, and p-AKT in SNU-1 
cells were determined using Western blot analysis. To confirm that ERBB2 is a direct target of miR-133a, a 
luciferase reporter assay was performed. Results showed that miR-133a overexpression inhibited SNU-1 cell 
proliferation and increased apoptosis. ERBB2 was a direct target of miR-133a, and it was negatively regulated 
by miR-133a. Interestingly, ERBB2 silencing has a similar impact to miR-133a overexpression, in that it significantly induced apoptosis and inhibited ERK and AKT activation. Our study showed that miR-133a inhibits 
the proliferation of gastric cancer cells by downregulating the expression of ERBB2 and its downstream signaling molecules p-ERK1/2 and p-AKT. Therefore, miR-133a might be used as a therapeutic target for treating 
gastric cancer.},
DOI = {10.3727/096504021X16240202940003}
}